不同病理学类型肺癌患者合并代谢综合征和非酒精性脂肪性肝病发生率调查*

doi:10.3969/j.issn.1672-5069.2016.03.009

实用肝脏病杂志 ›› 2016, Vol. 19 ›› Issue (3): 288-291.doi: 10.3969/j.issn.1672-5069.2016.03.009

不同病理学类型肺癌患者合并代谢综合征和非酒精性脂肪性肝病发生率调查*

朱婵艳，瞿冀琛，曹海霞，陈光榆，朱佩，章瑞楠，陈一铭，孙婉璐，杨蕊旭，颜士岩，范建高

200092 上海市上海交通大学医学院附属新华医院消化科（朱婵艳，曹海霞，陈光榆，章瑞楠，颜士岩，陈一铭，孙婉璐，杨蕊旭，范建高）；附属瑞金医院消化科（朱佩）；上海市肺科医院（瞿冀琛）

收稿日期:2015-09-16 出版日期:2016-05-10 发布日期:2016-05-20
通讯作者: 范建高，E-mail：fattyliver2004@126.com
作者简介:朱婵艳，女，26岁，医学博士，住院医师。主要从事慢性肝病与恶性肿瘤的关系研究。E-mail：zhuchanyan19890730@163.com
基金资助:
国家973课题（编号：2012CB517501）；国家自然科学基金项目（编号：81070322/81270491）；上海市科委重点项目（编号：09140903500/10411956300）；上海市卫生系统优秀学科带头人计划项目（编号：XBR2011007）

Incidence of metabolic syndrome and non-alcoholic fatty liver diseases in patients with different histological types of lung cancer

Zhu Chanyan，Qu Jichen，Cao Haixia，et al.

Department of Gastroenterology，Xinhua Hospital，Shanghai Jiaotong University School of Medicine，Shanghai 200092，China

Received:2015-09-16 Online:2016-05-10 Published:2016-05-20

摘要/Abstract

摘要： 目的探讨肺癌患者代谢综合征（MetS）和非酒精性脂肪性肝病（NAFLD）的患病率。方法回顾性分析2013年上海市肺科医院经病理学确诊的肺癌患者的临床资料，使用日立700全自动生化分析仪检测血生化指标，使用美国GE公司高档Vivid7 彩色多普勒超声诊断仪或美国西门子公司SONOLINE G50彩色多普勒超声诊断仪诊断NAFLD。结果在675例肺癌患者中，男性391例（57.9%），女性284例（42.1%），平均年龄（59.7±9.71）岁。其中165例（24.4%）患者合并MetS；在148例鳞癌、456例腺癌、11例小细胞肺癌、60例其他病理类型患者中，分别有33例（22.3%）、117例（25.7%）、2例（18.2%）、13 例(21.7%)患者合并MetS，不同病理类型的肺癌患者之间MetS患病率无显著统计学差异（x2=1.244，P=0.743）；148例鳞癌与456例腺癌患者合并肥胖症、低HDL血症、高血糖和高血压百分比无显著性相差，仅腺癌患者合并高TG血症百分比显著高于鳞癌患者（25.4%对17.4%，P=0.046）；456例腺癌与219例非腺癌患者合并MetS或NAFLD百分比均无显著性相差（P>0.05）。结论高TG血症和NAFLD可能与肺腺癌的发生相关。

关键词: 肺癌, 代谢综合征, 非酒精性脂肪性肝病, 高甘油三酯血症

Abstract: Objective To explore the prevalence of metabolic syndrome（MetS） and non-alcoholic fatty liver diseases（NAFLD） in patients with lung cancer. Methods We retrospectively analyzed the clinical data of patients with lung cancer in Shanghai Pulmonary Hospital in 2013. The results of biochemical indexes were obtained by Hitachi 700 full-automatic biochemical analyzers，and the diagnosis of NAFLD was made by Vivid 7 color dropper ultasound instruments from GE company or SONOLINE 50 color dropper ultasound instruments from SIMENS company. Results Among 675 patients with lung cancer，391（57.9%） were male and 284 （42.1%） female with the average age of （59.7±9.71） yr old；165 （24.4%） cases had MetS，and the prevalences of MetS in patients with adenocarcinoma，squamous cell carcinoma，small cell lung cancer and other types of lung cancer was 25.7% （117/456），22.3% （33/148），21.1%（15/71）and 21.1% （15/71），and the differences among them were not significantly（x2=1.244，P=0.743）；the proportion of elevated serum triglycerides in pulmonary adenocarcinoma was higher than in with squamous cell lung carcinoma（25.4% vs. 17.4%，P=0.047）；There was no significant difference as respect to the prevalence of MetS and/or NAFLD between 456 patients with adenocarcinoma and 219 with non-adenocarcinoma（P＞0.05）. Conclusion Hypertriglyceridemia and NAFLD might be the risk factors for the occurrence of lung adenocarcinoma.

Key words: Lung cancer, Metabolic syndrome, Non-alcoholic fatty liver diseases, Hypertriglyceridemia

朱婵艳，瞿冀琛，曹海霞，陈光榆，朱佩，章瑞楠，陈一铭，孙婉璐，杨蕊旭，颜士岩，范建高. 不同病理学类型肺癌患者合并代谢综合征和非酒精性脂肪性肝病发生率调查*[J]. 实用肝脏病杂志, 2016, 19(3): 288-291.

Zhu Chanyan,Qu Jichen,Cao Haixia,et al.. Incidence of metabolic syndrome and non-alcoholic fatty liver diseases in patients with different histological types of lung cancer[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 288-291.

参考文献

[1] 范建高. 代谢综合征与脂肪肝. 国外医学：内分泌学分册, 2002，34:273-275.
[2] Fan JG，Peng YD. Metabolic syndrome and non-alcoholic fatty liver disease:Asian definitions and Asian studies. Hepatobiliary Pancreat Dis Int，2007，6:572-578.
[3] Chalasani N，Younossi Z，Lavine JE，et al. The diagnosis and management of non-alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association，American Association for the Study of Liver Diseases，and American College of Gastroenterology. Gastroenterology，2012，142:1592-1609.
[4] Fan JG，Jia JD，Li YM，et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease:update 2010: （published in Chinese on Chinese Journal of Hepatology 2010; 18:163-166）. J Dig Dis，2011，12:38-44.
[5] Newsome PN，Allison ME，Andrews PA，et al. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut，2012，61:484-500.
[6] Esposito K，Chiodini P，Colao A，et al. Metabolic syndrome and risk of cancer:a systematic review and meta-analysis. Diabetes Care，2012，35:2402-2411.
[7] Dela Cruz CS，Tanoue LT，Matthay RA. Lung cancer: epidemiology，etiology，and prevention. Clin Chest Med，2011，32:605-644.
[8] Grundy SM，Cleeman JI，Daniels SR，et al. Diagnosis and management of the metabolic syndrome:an American Heart Association/National Heart，Lung，and Blood Institute scientific statement. Curr Opin Cardiol，2006，21:1-6.
[9] Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet，2004，363:157-163.
[10] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南（2010年修订版）. 中华肝脏病杂志， 2010，18:163-166.
[11] 王吉耀. 内科学. 北京: 人民卫生出版社，2010:318-322.
[12] Alberti KG，Zimmet PZ. Definition，diagnosis and classification of diabetes mellitus and its complications. Part 1:diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med，1998，15:539-553.
[13] 中华医学会糖尿病学分会代谢综合征研究协作组. 中华医学会糖尿病学分会关于代谢综合征的建议. 中华糖尿病杂志， 2004，12:156-161.
[14] Alberti KG，Zimmet P，Shaw J，et al. The metabolic syndrome-
a new worldwide definition. Lancet，2005，366:1059-1062.
[15] 宗文红，刘月星，顾竞春. 上海市闸北区社区居民代谢综合征流行现状及相关影响因素研究. 中国全科医学，2012，15:3103-3108.
[16] Fan JG，Zhu J，Li XJ，et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol， 2005，20:1825-1832.
[17] Okazaki I，Ishikawa S，Sohara Y. Genes associated with succeptibility to lung adenocarcinoma among never smokers suggest the mechanism of disease. Anticancer Res，2014，34:5229-5240.
[18] Ahn J，Lim U，Weinstein SJ，et al. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev，2009，18:2814-2821.
[19] Chi PD，Liu W，Chen H，et al. High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma. PLoS One，2014，9:e91080.
[20] Siemianowicz K，Gminski J，Stajszczyk M，et al. Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer. Int J Mol Med，2000，6:307-311.
[21] Fan JG，Saibara T，Chitturi S，et al. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific J Gastroenterol Hepatol ，2007，22:794-800.
[22] Wang FS，Fan JG，Zhang Z，et al. The global burden of liver disease:the major impact of China. Hepatology，2014，60:2099-2108.

不同病理学类型肺癌患者合并代谢综合征和非酒精性脂肪性肝病发生率调查*

Incidence of metabolic syndrome and non-alcoholic fatty liver diseases in patients with different histological types of lung cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[2]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[3]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[4]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[5]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[6]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[7]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[8]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[9]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[10]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.
[11]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.
[12]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[13]	张枫, 阎妍. 非酒精性脂肪性肝病患者血清载脂蛋白B水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 61-64.
[14]	宋娜, 刘晓燕, 刘畅, 山秀杰, 苏东峰, 李丽慧. 非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(1): 65-68.
[15]	崔清华, 陶红, 王晓玥, 张凤丽. 非酒精性脂肪性肝病患者血清糖化血红蛋白水平和心功能指标的变化研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 69-72.